According to the report, the Asia-Pacific Cell Counting Market Size is valued at USD 0.19 billion in 2021 and projected to grow at a CAGR of 7.2%, to reach USD 0.27 billion by 2026 during the forecast period 2021 to 2026.
The APAC cell counting market is expected to grow significantly during the forecast period. The growing demand for advanced healthcare facilities in emerging economies like China and the collaboration among market players for the development of innovative products are other factors which are significantly contributing to the growth of the market. Increased government funding for scientific research has fostered the rapid development of stem cell research in China. For example, the Chinese government and the UK government adopted a program related to stem cell research called the UK-China Stem Cell Partnership Initiative.
Factors that increase the cell counting market have focus on cell counting in the diagnosis and treatment of terminal diseases such as cancer, as well as a wide range of cell counting applications. For example, according to the American Cancer Society, nearly 1,689,000 new cases of cancer are expected in 2018, and about 600,000 deaths from it. In addition, the increase in healthcare expenses and the use of new cell counting technologies have led to the growth of the market.
However, the high prices of advanced cell counting systems and the lack of awareness of researchers to use advanced cell counting techniques are limiting the growth of this market to some extent.
The cell counting market is expected to show a good growth due to the growing focus on regenerative medicine & a significant number of biotechnology and biopharmaceutical companies in the APAC regions.
High cost of instruments and lack of goof healthcare infrastructure in developing countries are challenging the market growth rate.
This research report on the Asia Pacific Cell Counting Market has been segmented and sub-segmented into the following categories.
By End User:
The increasing number of diagnostic procedures for various chronic diseases and the increasing availability of cost-effective diagnostic tests are driving the growth of the market. In addition, less complex regulations for drug development in the Asian region have boosted the growth of the market.
Japan accounts for the largest market share in the APAC cell counting market in 2019. The market growth is attributed to the development of medical devices, in addition to research and development activities. In addition, the major companies are involved in the export of medical devices by targeting developing markets to capture reasonable market share. In addition, according to the National Institute of Health, China has been able to establish around 110 stem cell banks; there are currently 11 stem cell drugs under approval, and in 2018, more than 410 stem cell clinical trials were registered in the country. Therefore, these initiatives towards stem cell therapy offer a vast opportunity for the cell counting industry.
India is considered the fastest growing market for medical device manufacturers. In India, the cell counting market is growing due to the availability of low cost raw materials, better access to labor and an increasing number of hospitals and healthcare facilities. India is one of the major destinations for medical tourism especially for orthopedic surgeries which further influences the growth of the market. There is a steady growth of this market in Australia and Republic of Korea during the forecast period 2020-2026.
Key Market Companies Operating the Asia Pacific Cell Counting Market are Thermo Fisher Scientific, Inc., Danaher Corporation, Agilent Technologies, Bio-Rad Laboratories, Merck Millipore, Inc., GE Healthcare, Becton, Dickinson and Company, and PerkinElmer, Inc.
1.1 Market Definition
1.2 Study Deliverables
1.3 Base Currency, Base Year and Forecast Periods
1.4 General Study Assumptions
2. Research Methodology
2.2 Research Phases
2.2.1 Secondary Research
2.2.2 Primary Research
2.2.3 Econometric Modelling
2.2.4 Expert Validation
2.3 Analysis Design
2.4 Study Timeline
3.1 Executive Summary
3.2 Key Inferences
4. Drivers, Restraints, Opportunities, and Challenges Analysis (DROC)
4.1 Market Drivers
4.2 Market Restraints
4.3 Key Challenges
4.4 Current Opportunities in the Market
5. Market Segmentation
220.127.116.11 Cell Counters
18.104.22.168.1 Automated Cell Counters
22.214.171.124.2 Hemocytometers and Manual Cell Counters
126.96.36.199 Hematology Analysers
188.8.131.52.1 Single-Mode Readers
184.108.40.206.2 Multi-Mode Readers
220.127.116.11 Flow Cytometer
18.104.22.168 Assay Kits
5.1.4 Y-o-Y Growth Analysis, By Product
5.1.5 Market Attractiveness Analysis, By Product
5.1.6 Market Share Analysis, By Product
5.2.2 Pharmaceutical & Biotechnology Industries
5.2.3 Hospitals & Diagnostic Laboratories
5.2.4 Research & Academic Institutes
5.2.6 Y-o-Y Growth Analysis, By End-user
5.2.7 Market Attractiveness Analysis, By End-user
5.2.8 Market Share Analysis, By End-user
6. Geographical Analysis
6.1.1 Regional Trends
6.1.2 Impact Analysis
6.1.3 Y-o-Y Growth Analysis
22.214.171.124 By Geographical Area
126.96.36.199 By Product
188.8.131.52 By End-user
6.1.4 Market Attractiveness Analysis
184.108.40.206 By Geographical Area
220.127.116.11 By Product
18.104.22.168 By End-user
6.1.5 Market Share Analysis
22.214.171.124 By Geographical Area
126.96.36.199 By Product
188.8.131.52 By End-user
6.5 South Korea
6.7 Rest of Asia Pacific
7. Strategic Analysis
7.1 PESTLE analysis
7.2 Porter’s Five analysis
7.2.1 Bargaining Power of Suppliers
7.2.2 Bargaining Power of Consumers
7.2.3 Threat of New Entrants
7.2.4 Threat of Substitute Products and Services
7.2.5 Competitive Rivalry within the Industry
8. Market Leaders' Analysis
8.1 Thermo Fisher Scientific, Inc.,
8.1.2 Product Analysis
8.1.3 Financial analysis
8.1.4 Recent Developments
8.1.5 SWOT analysis
8.1.6 Analyst View
8.2 Danaher Corporation
8.3 Agilent Technologies
8.4 Bio-Rad Laboratories
8.5 Merck Millipore, Inc.,
8.6 GE Healthcare
8.7 Becton, Dickinson and Company
8.8 PerkinElmer, Inc.
9. Competitive Landscape
9.1 Market share analysis
9.2 Merger and Acquisition Analysis
9.3 Agreements, Collaborations, and Joint Ventures
9.4 New Product Launches
10. Market Outlook and Investment Opportunities
a) List of Tables
b) List of Figures